FDA Accepts BLA for Ivonescimab in NSCLC, Sets November 2026 PDUFA Date
Summary
The FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in EGFR-mutated NSCLC and set a PDUFA goal action date of November 14, 2026.
Key Events
-
FDA Accepts BLA for Ivonescimab
The U.S. Food & Drug Administration (FDA) has accepted for filing Summit Therapeutics' Biologics License Application (BLA) for ivonescimab.
-
PDUFA Goal Date Set
The FDA has provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026, for a decision on the application.
-
Application Based on HARMONi Study
The BLA seeks approval for ivonescimab in combination with chemotherapy for EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) therapy, based on results from the Phase III HARMONi trial.
Analysis
Summit Therapeutics announced that the FDA has accepted its Biologics License Application (BLA) for ivonescimab, a significant regulatory milestone following the BLA submission on January 12, 2026. The acceptance confirms the FDA has deemed the application complete and ready for substantive review. The assigned PDUFA goal action date of November 14, 2026, provides a clear timeline for a potential approval decision, which is crucial for investors tracking the commercialization prospects of this key oncology asset. This development de-risks the regulatory pathway for ivonescimab in EGFR-mutated non-small cell lung cancer, a market with substantial unmet need.
At the time of this filing, SMMT was trading at $16.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6B. The 52-week trading range was $15.45 to $36.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.